
Quarterly report 2025-Q3
added 11-06-2025
Caladrius Biosciences Net Debt 2011-2025 | CLBS
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Caladrius Biosciences
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -22.3 M | -31.7 M | -23.9 M | -15.9 M | -13.7 M | -10.3 M | -29 M | -7.91 M | -3.54 M | -2.53 M | -42 M | -9.92 M | 3.11 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.11 M | -42 M | -16.1 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
ARCA biopharma
ABIO
|
-60.6 M | - | 1052.0 % | $ 415 M | ||
|
AbbVie
ABBV
|
61.5 B | $ 223.01 | -0.99 % | $ 395 B | ||
|
Alpine Immune Sciences
ALPN
|
-63.9 M | - | - | $ 2.17 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
-107 M | $ 4.68 | 1.85 % | $ 777 M | ||
|
Aclaris Therapeutics
ACRS
|
-22 M | $ 3.38 | 3.21 % | $ 261 M | ||
|
AlloVir
ALVR
|
-62.7 M | - | 4.14 % | $ 49.1 M | ||
|
Acasti Pharma
ACST
|
-27.4 M | - | 4.01 % | $ 150 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
-119 M | - | -15.15 % | $ 60.3 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-12 M | - | -11.43 % | $ 502 K | ||
|
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | ||
|
Ascendis Pharma A/S
ASND
|
-195 M | $ 212.3 | 5.5 % | $ 5 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | ||
|
Albireo Pharma
ALBO
|
-239 M | - | -0.23 % | $ 916 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-657 K | - | - | $ 7.46 M | ||
|
Aptorum Group Limited
APM
|
-2.77 M | $ 1.33 | -1.48 % | $ 7.25 M | ||
|
Alterity Therapeutics Limited
ATHE
|
-34.7 M | $ 3.4 | 1.49 % | $ 8.18 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | ||
|
AstraZeneca PLC
AZN
|
9.86 B | $ 90.34 | -1.28 % | $ 96.9 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
469 M | $ 25.76 | 0.19 % | $ 1.25 B | ||
|
Anika Therapeutics
ANIK
|
-46 M | $ 9.53 | -1.19 % | $ 140 M | ||
|
Brickell Biotech
BBI
|
-29.7 M | - | -5.38 % | $ 6.06 M | ||
|
BeiGene, Ltd.
BGNE
|
-2.44 B | - | 0.49 % | $ 251 B | ||
|
Biogen
BIIB
|
4.01 B | $ 173.03 | -2.55 % | $ 25.2 B | ||
|
BioVie
BIVI
|
-17.2 M | $ 1.54 | -2.53 % | $ 2.28 M | ||
|
Bellicum Pharmaceuticals
BLCM
|
-34.7 M | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
-60.5 M | - | -7.31 % | $ 87 M | ||
|
Aytu BioScience
AYTU
|
-19.9 M | $ 2.33 | 2.3 % | $ 14.6 M | ||
|
Arena Pharmaceuticals
ARNA
|
-25.4 M | - | -6.81 % | $ 3.04 B | ||
|
Baudax Bio
BXRX
|
1.86 M | - | 0.59 % | $ 63 K | ||
|
Avenue Therapeutics
ATXI
|
-3.13 K | - | -52.27 % | $ 4.45 M | ||
|
Catalyst Biosciences
CBIO
|
-33.1 M | $ 15.32 | 5.73 % | $ 1.01 B | ||
|
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - | ||
|
ChromaDex Corporation
CDXC
|
-26.5 M | - | -0.88 % | $ 598 M | ||
|
Axon Enterprise
AXON
|
-404 M | $ 586.28 | 3.15 % | $ 44.4 B | ||
|
Cerus Corporation
CERS
|
-6.33 M | $ 2.14 | 13.23 % | $ 395 M | ||
|
Checkpoint Therapeutics
CKPT
|
-40.8 M | - | - | $ 169 M | ||
|
Celldex Therapeutics
CLDX
|
-24.5 M | $ 28.33 | 0.5 % | $ 1.82 M | ||
|
Cellectar Biosciences
CLRB
|
-9.01 M | $ 3.81 | -5.35 % | $ 46.6 M | ||
|
Clovis Oncology
CLVS
|
293 M | - | -7.23 % | $ 13 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-3.5 M | $ 0.29 | -5.01 % | $ 631 M | ||
|
Cortexyme
CRTX
|
-68.6 M | - | -1.05 % | $ 67.1 M | ||
|
Benitec Biopharma
BNTC
|
-1.92 M | $ 12.91 | 0.78 % | $ 531 M | ||
|
Cytokinetics, Incorporated
CYTK
|
17.3 M | $ 60.38 | 0.11 % | $ 6.76 M | ||
|
BioNTech SE
BNTX
|
-973 M | $ 95.9 | 0.17 % | $ 27.2 B | ||
|
Deciphera Pharmaceuticals
DCPH
|
-57.6 M | - | - | $ 2.18 B | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
455 M | $ 11.55 | 8.86 % | $ 747 M | ||
|
Dynavax Technologies Corporation
DVAX
|
-65.3 M | $ 10.89 | -0.09 % | $ 1.42 B | ||
|
Eloxx Pharmaceuticals
ELOX
|
-9.94 M | - | -5.68 % | $ 8.28 M | ||
|
Acer Therapeutics
ACER
|
-2.08 M | - | 2.71 % | $ 14 M |